Expected Moves

Oct 27, 2026→Nov 10, 2026

Feb 10, 2027→Feb 24, 2027

H1 2027 Earnings Release assessing the turnaround of the plasma collection margin, KCENTRA challenges, and underlying NPAT growth.

May 18, 2027→Jun 2, 2027

Mid-year operational update exposing the stock to macro-policy shifts, Medicare Part D impacts, and global pricing discussions.

Aug 17, 2027→Aug 31, 2027

FY2027 Earnings Release, representing the full-year scorecard for the cost-optimization strategy and albumin sales recovery in China.